Article
Dentistry, Oral Surgery & Medicine
Kerstin M. Galler, Eva-Maria Gratz, Matthias Widbiller, Wolfgang Buchalla, Helge Knuttel
Summary: This scoping review systematically explores the cellular and molecular processes of trauma-associated root resorption, revealing a lack of discussion on the pathophysiological mechanisms in the literature. Further research is needed to address these gaps.
Article
Pharmacology & Pharmacy
Qian Lu, Chao Jiang, Jialong Hou, Hao Qian, Feifan Chu, Weiqi Zhang, Mengke Ye, Ziyi Chen, Jian Liu, Hanbing Yao, Jianfeng Zhang, Jiake Xu, Te Wang, Shunwu Fan, Qingqing Wang
Summary: The incidence of osteoporosis is increasing, especially in postmenopausal women. Patchouli alcohol (PA), a natural compound with anti-inflammatory effects, has shown inhibitory effects on osteoclasts and may be a potential treatment for osteoporosis in the future.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Huijiang Liu, Ronghe Gu, Qian Huang, Yun Liu, Chong Liu, Shijie Liao, Wenyu Feng, Tianyu Xie, Jinmin Zhao, Jiake Xu, Qian Liu, Xinli Zhan
Summary: This study found that isoliensinine can inhibit the differentiation of osteoclasts and reduce bone loss, showing great potential for treating osteoporosis.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Endocrinology & Metabolism
Michael Frech, Gregor Schuster, Fabian T. Andes, Georg Schett, Mario M. Zaiss, Kerstin Sarter
Summary: The study revealed the involvement of the immunomodulatory molecule Btn2a2 in osteoclast differentiation and function, with potential implications in bone homeostasis. Btn2a2 deficiency led to abnormal osteoclast function and numbers, affecting bone architecture.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Pharmacology & Pharmacy
Kaiqiang Sun, Jian Zhu, Yi Deng, Ximing Xu, Fanqi Kong, Xiaofei Sun, Le Huan, Changzhen Ren, Jingchuan Sun, Jiangang Shi
Summary: Osteolytic bone disease, caused by imbalanced bone homeostasis, can lead to high risk of skeletal fragility and fracture in old and postmenopausal women. Previous studies suggest the potential of traditional Chinese medicine gamabufotalin (CS-6) in inhibiting osteolytic conditions.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Pharmacology & Pharmacy
Yongchao Zhao, Guoxi Shao, Xingang Liu, Zhengwei Li
Summary: This review comprehensively summarizes the current understanding of melatonin's regulation of bone metabolism, including its effects on mesenchymal stem cells and bone cells to promote bone formation and inhibit bone resorption. Experimental studies and clinical trials have shown that melatonin has a protective effect against osteoporosis and may be a potential novel therapy for this condition.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Yanhui Tan, Minhong Ke, Zhichao Li, Yan Chen, Jiehuang Zheng, Yiyuan Wang, Xuefeng Zhou, Gang Huang, Xiaojuan Li
Summary: Insulicolide A inhibits osteoclast differentiation both in vitro and in vivo, suggesting its potential as a treatment for osteoclast-related diseases.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Qiang Xu, Guiping Chen, Huaen Xu, Guoming Xia, Meisong Zhu, Haibo Zhan, Bin Zhang, Min Dai, Hongxian Fan, Xuqiang Liu
Summary: Celastrol has shown promising potential in preventing aseptic prosthetic loosening and osteoporosis by inhibiting osteoclast formation and function, making it a potential treatment for osteolytic diseases induced by disrupted osteoclast function.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Chemistry, Medicinal
Zhihao Chen, Karthik Rajan Rajamanickam, Mina Ding, Sang Kyoon Kim, Sang-wook Park, Eunae Kim, Sunwoo Lee, Tae-Hoon Lee
Summary: In this study, we discovered a potent candidate, PMSA derivative 11, for suppressing mature osteoclasts formation in vitro through a TRAP staining assay. The bioactivity of PMSA derivatives was evaluated and 11 showed the most promising bioactivity, with an IC50 value of 322.9 nM, which was 15-fold better than PMSA-3-Ac. Mechanistically, 11 decreased the expression of genes required for osteoclastogenesis by blocking NFATc1 translocation. In vivo investigation demonstrated that 11 prevented excessive osteoclastogenesis-mediated bone loss in ovariectomized osteoporosis mimic mice. These findings highlight the therapeutic potential of 11 as a lead compound for anti-osteoporosis by targeting NFATc1 translocation.
JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Biochemistry & Molecular Biology
Yuria Jang, Hong Moon Sohn, Young Jong Ko, Hoon Hyun, Wonbong Lim
Summary: The mutant RANKL demonstrated the ability to inhibit osteoclastogenesis by competitively inhibiting RANKL, serving as a potential therapeutic agent for osteoporosis with fewer toxic side effects compared to traditional treatments.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Plant Sciences
Yo-Seob Seo, Hyang Lim, Jeong-Yeon Seo, Kyeong-Rok Kang, Do Kyung Kim, Hyun-Hwa Lee, Deuk-Sil Oh, Jae-Sung Kim
Summary: The purpose of this study was to evaluate the anti-osteoporosis effects of Osmanthus fragrans leaf ethanol extract (OFLEE) in both bone marrow-derived macrophages (BMM) and animals with osteoporosis. OFLEE was found to suppress the formation of osteoclasts and the activation of various factors involved in osteoclastogenesis. It also downregulated several inflammatory factors and prevented osteoporotic bone loss in animals. These findings suggest that OFLEE could be a potential treatment option for osteoporosis.
Article
Biology
Lisha Li, Jing Zhou, Yingping Xu, Zengshu Huang, Na Zhang, Xuemin Qiu, Ling Wang
Summary: Inflammatory factors affect osteoblast and osteoclast activity in osteoporosis, and estrogen plays a role in bone metabolism through CCR6 signaling pathways. The study showed that CCR6 deletion reduced osteoblast activity and mineralization, while also influencing the expression of Osterix and RANKL, potentially regulating bone metabolism.
Review
Endocrinology & Metabolism
Shu-ting Lin, Yi-zhong Li, Xiao-qi Sun, Qian-qian Chen, Shun-fa Huang, Shu Lin, Si-qing Cai
Summary: The relationship between breast cancer and osteoporosis is influenced by factors such as estrogen, RANKL, and NPY. Treatment for breast cancer may increase the risk of osteoporosis, while Y1 and Y5 receptors are highly expressed in breast cancer and Y1 and Y2 receptors may affect osteogenic response.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Oncology
Tingting Wei, Zhiyi Shan, Xin Wen, Ning Zhao, Gang Shen
Summary: The present study investigated the alterations in cementocyte formation in response to orthodontic forces and found that cementocytes responded to the forces by modulating the RANKL/OPG ratio and SOST expression. The biological response of cementocytes played an important role in the mechanotransduction and homeostasis of tooth movement and root resorption.
MOLECULAR MEDICINE REPORTS
(2022)
Review
Cell Biology
Luodan Zhang, Fa Zeng, Minmin Jiang, Maozhen Han, Binbin Huang
Summary: This article reviews the potential role and therapeutic potential of osteoprotegerin in endocrine and metabolic diseases. It mainly focuses on the effects of osteoprotegerin through the RANKL/RANK/OPG system on various processes such as bone remodeling, vascular calcification, and beta-cell proliferation, providing a comprehensive understanding of osteoprotegerin as a potential drug for these diseases.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
